stockrow
Monday 9 November 2026
Export ANTX’s income statement to Excel — free account
AN2 Therapeutics, Inc.
ANTX- EPS
- +14.3%
- Free cash flow
- +7.91%
Quarter to June 2026, against a year earlier
4.00
0.04
+1.01%
Follow ANTX
Alert me
AN2 Therapeutics, Inc. (ANTX) P/E ratio
AN2 Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NGEN NervGen Pharma Corp. compare | n/m |
| MGNX MacroGenics, Inc. compare | n/m |
| ANTX AN2 Therapeutics, Inc. | n/m |
| IPHA Innate Pharma S.A. Sponsored ADR compare | n/m |
| SION Sionna Therapeutics, Inc. compare | n/m |
| CNTN Canton Strategic Holdings, Inc. compare | n/m |
| STRO Sutro Biopharma, Inc. compare | n/m |
| INO Inovio Pharmaceuticals, Inc. compare | n/m |
| VRXA Veraxa Biotech AG compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)